SUMMARY The results of a randomised controlled clinical study in the treatment of diabetic maculopathy are reported. Ninety-nine patients with two similarly affected eyes had one-chosen by random procedure-treated, while the other was left as an untreated control. Visual acuity was maintained in the treated eyes, while it deteriorated in the untreated eyes, reaching over 2 lines difference after 4 years. The difference in deterioration was significantly less in treated than in untreated eyes at each assessment. After 4 years the difference between the 2 eyes was greatest in those with initially good vision. There was no difference in visual acuity in patients whose initial vision was less than 6/36. Only 9 treated but 25 control eyes lost vision to blindness (P < 0f00 1). It is concluded that maculopathy is a treatable form of diabetic retinopathy if treated before severe visual loss occurs.
In diabetic retinopathy loss of visual acuity can result either from the sequelae of proliferative retinopathy or from maculopathy. During the last few years reports have been published showing the effectiveness of photocoagulation for proliferative retinopathy, especially when the optic disc is involved. '-4 There is much less evidence about the efficacy of treatment in diabetic maculopathy.
There are only 3 previous reports on randomised controlled studies of diabetic maculopathy.5-7 None of these followed up the patients for longer than 3 years. In our present paper we are reporting the results of treatment for diabetic maculopathy with xenon arc photocoagulation in the British Multicentre Study at a time when an important number of patients have been followed up for 5 years. 
Patients and methods
These were described in detail in 1975.7 A summary is given below.
DEFINITIONS
Macula was defined as the fovea and the area immediately surrounding it extending to approximately 1 disc diameter from the centre of the fovea in all directions.
Maculopathy was defined as a visual acuity of 6/9 or less on the Snellen test type in the presence of macular oedema in association with haemorrhages, microaneurysms, and exudates. Patients with a visual acuity better than 6/9 were included if ophthalmoscopically hard exudates were seen to encroach on the macula.
PATIENTS
Patients were included in the trial if they had diabetic maculopathy of a similar severity in both eyes. The mean visual acuity for treated eyes and untreated eyes was also calculated for each assessment. Plots were also made of initial visual acuity against annual visual acuity.
Results
A total of 99 patients were followed up for at least 1 year. Of these, 81 were followed up for at least 2 years, 71 for at least 3 years, 35 for at least 4 years, and 23 for 5 years. The mean age of entry to the trial was 58 4 years (range 20-76). Known duration of diabetes was 8-8 years (range 0-34). Three of the untreated eyes which became blind had new vessels present in the affected eye at the time of entry into the study. Vitreous haemorrhage caused severe visual loss (worse than 6/60) as a secondary cause in 6 untreated and 3 treated eyes. These eyes were already blind from maculopathy but retained navigational vision until the development of the haemorrhage. In 1 treated eye vitreous haemorrhage occurred after cataract extraction, and in another eye new vessels were not seen on any previous examination, probably because of lens opacities. Of the blind eyes 3 treated and 6 untreated eyes were already 6/60 at the initial assessment. Five treated eyes which had a visual acuity of 6/60 at entry into the study improved slightly during the follow-up, but none of the untreated eyes with such poor initial visual acuities showed improvement.
Discussion
This study confirms previous results6 7 that diabetic maculopathy benefits from treatment with xenon arc photocoagulation. There are, however, some important differences between the results reported here and those reported in 1975.7 In the previous report, while the initial visual acuity was similar in the treated and untreated eyes, at 1, 2, and 3 years the treated eyes had 1 line less deterioration of vision than the untreated eyes. This difference seemed to be constant, suggesting that photocoagulation delays but does not prevent deterioration of vision in this condition. The present report, which includes more patients followed up for a longer period of time, leads us to a different conclusion. Instead of the eyes deteriorating in parallel, with the treated eye having significantly better visual acuity than the untreated, we see that there is divergence increasing over the third, fourth, and fifth years. The treated eyes maintain their visual acuities, but those of the untreated group deteriorate.
That the divergence takes time to appear can be explained by several factors. In the absence of treatment macular oedema increases, but slowly, requiring 3 or more years to show its full effect. While the deposition of hard exudate in the fovea may reduce the visual acuity there is a delay period before the exudate is actually deposited in the small central area where it causes most harm to the vision.
The development of reduced capillary perfusion is slow. It During the period of this study we have become aware of the fact that maculopathy is not a single entity but comprises a variety of subgroups which are differentiated by the relationship of hard exudates and haemorrhages, ischaemia, and oedema. These features determine not only the initial visual acuity but also response to treatment. Subdivision into these subgroup depends on analysis of colour photographs and florescein angiograms and is in process.
The results reported in this paper were achieved with the xenon arc photocoagulator. The argon laser will probably be more rather than less effective in the treatment of maculopathy because of its smaller spot size. A randomised study using the laser is now starting in the USA. In the meantime it is suggested, as the result of the findings reported in this paper, that photocoagulation is an effective way of treating diabetic maculopathy and maintaining vision provided the initial acuity is better than 6/36. 
